<DOC>
	<DOCNO>NCT01644643</DOCNO>
	<brief_summary>To Evaluate Effects Ceftazidime-Avibactam Best Available Therapy patient complicate urinary tract infection complicate intra-abdominal infection .</brief_summary>
	<brief_title>Ceftazidime-Avibactam Treatment Infections Due Ceftazidime Resistant Pathogens</brief_title>
	<detailed_description>An Open-Label , Randomized , Multicenter , Phase III Study Ceftazidime Avibactam ( CAZ-AVI , formerly CAZ104 ) Best Available Therapy Treatment Infections Due Ceftazidime Resistant Gram Negative Pathogens</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam , ceftazidime drug combination</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Patient must ≥18 ≤90 year age Female patient participate surgically sterile complete menopause female capable child agree attempt pregnancy receive IV study therapy period 7 day Patient ceftazidimeresistant Gram negative pathogen isolate appropriate culture within 5 day prior study entry ( ie , within 5 day prior Screening ; studyqualifying culture ) , determine causative agent entry infection Patient APACHE II score &gt; 30 ( cIAI patient ) Patient infection due Gram negative pathogen unlikely respond CAZAVI treatment ( eg , Acinetobacter spp. , Stenotrophomonas spp . ) Patient receive hemodialysis peritoneal dialysis renal transplant Patient immunocompromised Patient rapidly progressive terminal illness high risk mortality due cause , include acute hepatic failure , respiratory failure severe septic shock unlikely survive 4 5week study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ceftazidime ,</keyword>
	<keyword>avibactam ,</keyword>
	<keyword>metronidazone ,</keyword>
	<keyword>Anti-Infectives</keyword>
</DOC>